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1635Elevated NT-proBNP independently predicts all-cause mortality
and morbidity of patients with AF. However, higher NT-proBNP
levels may be associated with different conditions, and the pivotal
roles of those factors evaluate further large-scale, prospective
randomized clinical trials. In addition, measuring not only NT pro-
BNP, but also troponin T and I (7), is an easy method to assess
increased risk for stroke and mortality in patients with AF. These
markers might be useful in clinical practice. Finally, one should
keep in mind that NT-proBNP alone without other predictive
markers may not give exact information to clinicians about the
prognostic indication of patients; thus, NT-proBNP should be
evaluated along with other serum mortality predictive markers.*Sevket Balta, MD
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Natriuretic Peptide May Be
Related to Very Different Conditions
We thankDr. Balta and colleagues for their comments on our article
concerning the use of N-terminal pro B-type natriuretic peptide(NT-proBNP) for atrial ﬁbrillation (AF) in the ARISTOTLE
(Apixaban for the Prevention of Stroke in Subjects With Atrial
Fibrillation) trial (1). Of the 18,201 patients with AF in the
ARISTOTLE trial, 14,892 comprised the population in whom
baseline NT-proBNP plasma samples were analyzed. The results
showed that NT-proBNPwas strongly and independently related to
stroke, cardiovascular events, and mortality.
As Dr. Balta and colleagues point out, several states may affect
NT-proBNP levels (2,3). However, it is important to view this in
the context of the current study. Reversible causes of AF (e.g.,
infection, sepsis acute lung disease exacerbation, and thyrotoxicosis)
were excluded, and patients were generally stable at the time of
enrollment with regard to other medical illnesses (4). Moreover,
adjustments were performed with Cox proportional hazards models
for established risk factors, including heart failure, renal function,
and biomarkers of myocardial damage measured with troponin. It is
true that a large number of factors, including lung disease, will
contribute to elevation of NT-proBNP, and some of these no
doubt contributed to the pathophysiologic link of NT-proBNP
elevation and clinical events. Irrespective of the mechanism,
however, what we showed was that the information obtained
from NT-proBNP levels, in addition to the clinical risk factors,
provided independent prognostic information in the population
with AF.
It is well known that various equations used to estimate renal
function have their strengths and weaknesses, and we can reassure
Dr. Balta and colleagues that our ﬁndings were not dependent on
the Cockcroft-Gault formula because we used cystatin C as the
biomarker to reﬂect renal function. This newer marker of renal
function does not depend on age for estimating the glomerular
ﬁltration rate; moreover, it is a well-established marker of cardio-
vascular events (5,6).
At present, guidelines recommend screening of patients with
newly detected AF with echocardiography to identify underlying
structural pathologies and potential reversible causes of AF and to
tailor treatments. There are a large number of reported echocar-
diographic measures of diastolic function, including left atrial size,
that relate to stroke risk, but with little consensus as to how to
simply and reliably incorporate these into risk assessment.
However, for prediction of the risk of thromboembolic events,
a complementary measurement of NT-proBNP is attractive as an
easily available tool to provide further guidance on management.
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Response to Antiplatelet Therapy
in Patients With ST-Segment
Elevation Myocardial Infarction
We read with interest the paper by Parodi et al. (1) in a previous
issue of the Journal. The authors found that prasugrel and ticagrelor
provided an effective platelet inhibition 2 h after the loading dose in
only half of the patients with ST-segment elevation myocardial
infarction treated with percutaneous coronary intervention, and at
least 4 h were required to achieve an effective platelet inhibition in
the majority of patients.
Although their ﬁndings are interesting, other factors involved in
platelet reactivity have not been completely evaluated. It should be
noted that the individual platelet response to antiplatelet therapy
depends on a network of mechanisms, including genetic factors,
cellular factors (accelerated platelet turnover, reduced cytochrome
CYP3A metabolic activity, increased adenosine-diphosphate expo-
sure, up-regulation of P2Y12 pathways), clinical factors (age, dia-
betes, body mass index, left ventricle ejection function,
inﬂammation, elevated plasma ﬁbrinogen, extent of coronary artery
disease [CAD], number and complexity of CAD lesions, creatinine
clearance, comorbidities, noncompliance, underdosing, poor
absorption, drug-to-drug interactions, smoking), and environmentalfactors (geographic origin) (2–4). In this setting, we have investi-
gated the effect of theCYP2C19 polymorphism on platelet reactivity,
vascular function, and cardiovascular outcome in patients with
CAD.We found that that the CYP2C19*2 polymorphism is a factor
associated with a higher rate of major adverse cardiovascular events
and signiﬁcantly increased platelet reactivity units (PRU) (5,6). Our
ﬁndings indicate that genetic factors play an important role in PRU
and prognosis.
Moreover, in another study, in patients treated with percutaneous
coronary intervention, baseline PRU values are inﬂuenced by several
confounding factors, especially acute atherothrombotic events and
inﬂammation (7). Parodi et al. (1) concluded that the independent
predictors of high residual platelet reactivity at 2 h were morphine
use and baseline PRU value, but we believe that the total appraisal
must also admeasure the contribution of other factors, such as the
severity of myocardial infarction and inﬂammation, which affects
platelet reactivity, in the prediction of high residual platelet reactivity
at 2 h.
Thus, the precise deﬁnition of multiple genetic, cellular, and
clinical determinants inﬂuencing platelet reactivity will lead to
a more individualized and effective adjustment of antiplatelet
treatment for acute myocardial infarction, coronary stenting, and
cardiovascular outcome.
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